SCHEMBL2578488

SCHEMBL2578488

CN(C)CCn1cc(-c2cccc(-c3ccccc3)c2)c(O)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.39
MAPK3 P27361 2/20 0.39
MAPK1 P28482 2/20 0.39
NR5A2 O00482 1/20 0.38
HTR7 P34969 3/20 0.36
HTR1A P08908 2/20 0.36
MAP4K4 O95819 2/20 0.36
TGFBR1 P36897 2/20 0.36
COMT P21964 1/20 0.36
ESRRG P62508 1/20 0.36
LSS P48449 1/20 0.35
PTGIR P43119 1/20 0.35
OPRD1 P41143 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HDAC3 O15379 4/20 0.34
HDAC4 P56524 4/20 0.34
HDAC1 Q13547 4/20 0.34
HDAC7 Q8WUI4 4/20 0.34
HDAC2 Q92769 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386926 0.90 PTGIR (0.42) BRAFMAPK3MAPK1HTR7HTR1A
SCHEMBL2577961 0.90 BRAF (0.39) BRAFMAPK3MAPK1NR5A2HTR7
Hydrochloric Acid SCHEMBL2579512 0.89 BRAF (0.38) BRAFMAPK3MAPK1NR5A2HTR7
Hydrochloric Acid SCHEMBL2580812 0.89 ESRRG (0.43) BRAFMAPK3MAPK1HTR7HTR1A
SCHEMBL2580954 0.86 BRD4 (0.39) BRAFMAPK3MAPK1NR5A2HTR7
SCHEMBL5743254 0.84 SLC6A9 (0.38) BRAFMAPK3MAPK1MAP4K4TGFBR1
SCHEMBL1385611 0.83 PTGIR (0.44) BRAFMAPK3MAPK1HTR7HTR1A
Hydrochloric Acid SCHEMBL27666333 0.83 SLC6A9 (0.38) BRAFMAPK3MAPK1MAP4K4TGFBR1
Hydrochloric Acid SCHEMBL2579363 0.82 PTGIR (0.43) BRAFMAPK3MAPK1HTR7HTR1A
SCHEMBL1385292 0.80 PTGIR (0.45) PTGIR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524838-B2 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA S.A. (FR) 2009-04-28 US claimed
EP-1689720-B1 PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS AVENTIS PHARMA SA (FR) 2009-04-15 EP claimed
US-20050165005-A1 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA S.A. (FR) 2005-07-28 US claimed
US-8048893-B2 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA SA (FR) 2011-11-01 US disclosed
US-20090170833-A1 PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA S.A. (FR) 2009-07-02 US disclosed
US-7524838-B2 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA S.A. (FR) 2009-04-28 US disclosed
EP-1689720-B1 PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS AVENTIS PHARMA SA (FR) 2009-04-15 EP disclosed
EP-1689720-A1 PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS Aventis Pharma S.A. (FR) 2006-08-16 EP disclosed
WO-2005051917-A9 PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS AVENTIS PHARMA SA (FR) 2005-09-29 WO disclosed
US-20050165005-A1 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA S.A. (FR) 2005-07-28 US disclosed
WO-2005051917-A1 PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS AVENTIS PHARMA S.A. (FR) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170833-A1 PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM C1R, CBR3, C3AR1 BRAF 1243/4885MAPK3 635/4885MAPK1 2467/4885
US-20050165005-A1 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them C1R, CBR3, C3AR1 BRAF 1200/4885MAPK3 614/4885MAPK1 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.